EPRX – eupraxia pharmaceuticals inc. (US:NASDAQ)
Stock Stats
News
Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis [Yahoo! Finance]
Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $12.00 price target on the stock.
Eupraxia Pharmaceuticals Announces CFO Succession [Yahoo! Finance]
Eupraxia Pharmaceuticals Announces CFO Succession [Globe and Mail, The (Toronto, Canada)]
Form 6-K EUPRAXIA PHARMACEUTICALS For: Feb 25
Form 6-K EUPRAXIA PHARMACEUTICALS For: Feb 18
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.